Evidence map›Paper›PMID 31853245›Full record

ArticleJournal of geriatric cardiology : JGC2019

Major bleeding events in octagenarians associated with drug interactions between dabigatran and P-gp inhibitors.

Marjorie Bernier, Sarah-Line Lancrerot, Fanny Rocher, Elise K Van-Obberghen, Pierre Olivier, Thibaud Lavrut, Nadège Parassol-Girard, Milou-Daniel Drici

Abstract read
In one paragraph

Article in Journal of geriatric cardiology : JGC, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.6field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Marjorie BernierDepartment of Pharmacology and Toxicology, PharmacoVigilance Center, University of Nice Côte d'Azur Medical Center, Hôpital de Cimiez, 4 Avenue Reine Victoria, BP 1179, 06003, Nice, France.
Sarah-Line LancrerotDepartment of Pharmacology and Toxicology, PharmacoVigilance Center, University of Nice Côte d'Azur Medical Center, Hôpital de Cimiez, 4 Avenue Reine Victoria, BP 1179, 06003, Nice, France.
Fanny RocherDepartment of Pharmacology and Toxicology, PharmacoVigilance Center, University of Nice Côte d'Azur Medical Center, Hôpital de Cimiez, 4 Avenue Reine Victoria, BP 1179, 06003, Nice, France.
Elise K Van-ObberghenDepartment of Pharmacology and Toxicology, PharmacoVigilance Center, University of Nice Côte d'Azur Medical Center, Hôpital de Cimiez, 4 Avenue Reine Victoria, BP 1179, 06003, Nice, France.
Pierre OlivierEmergency Department Short Stay Unit, University of Nice Côte d'Azur Medical Center, Hôpital Pasteur 2, 30, Voie Romaine 06001, Nice, France.
Thibaud LavrutDepartment of Pharmacology and Toxicology, PharmacoVigilance Center, University of Nice Côte d'Azur Medical Center, Hôpital de Cimiez, 4 Avenue Reine Victoria, BP 1179, 06003, Nice, France.
Nadège Parassol-GirardDepartment of Pharmacology and Toxicology, PharmacoVigilance Center, University of Nice Côte d'Azur Medical Center, Hôpital de Cimiez, 4 Avenue Reine Victoria, BP 1179, 06003, Nice, France.
Milou-Daniel DriciDepartment of Pharmacology and Toxicology, PharmacoVigilance Center, University of Nice Côte d'Azur Medical Center, Hôpital de Cimiez, 4 Avenue Reine Victoria, BP 1179, 06003, Nice, France.
Institut de Chimie de Nice · FRHôpital Pasteur · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe direct oral anticoagulant dabigatran does not require any routine therapeutic drug monitoring. Yet, concerns about possible drug interactions susceptible to increase its inherent bleeding risk, especially in very elderly patients, have been raised recently. The aim of our study was to evaluate to what extent the co-prescription of P-gp inhibitors with dabigatran may increase its plasma levels and lead to bleeding complications, in usual conditions of care of the very elderly.

methodsFifty-eight patients over 85 years old with non valvular atrial fibrillation receiving dabigatran were included in a prospective cohort. Prescriptions were screened for the presence of P-gp inhibitors (Group A) or not (Group B).

resultsPatients from Group A had increased dabigatran mean plasma concentrations as compared with patients from Group B (A

conclusionIn our cohort of very elderly patients, at least, the co-prescription of dabigatran with P-gp inhibitors in usual conditions of care resulted in higher dabigatran plasma concentrations and more frequent bleeding occurrences.

Indexed as

DabigatranDrug interactionHemorrhageP-gp inhibitors, The elderly

Identifiers

PMID31853245
PMCPMC6911799
OpenAlexW2992794955

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.